Pharmacodynamics — Receptors and Dose-Response

Receptor Structure and Classification

• Receptor Occupancy and Signal Transduction: Drug binding causes conformational changes in receptor structure that expose or activate intracellular domains. For GPCRs, this permits coupling to G proteins (Gs, Gi, Gq families) that activate second-messenger systems: Gs-coupled receptors increase cAMP via adenylyl cyclase; Gi-coupled receptors decrease cAMP; and Gq-coupled receptors activate phospholipase C, generating IP3 and diacylglycerol. RTKs autophosphorylate tyrosine residues upon ligand binding, creating docking sites for adaptor proteins that activate mitogen-activated protein kinase (MAPK) cascades. This multiplicity of pathways explains why different drugs targeting the same receptor may have distinct clinical effects—beta-blockers block Gi-coupled signaling to reduce heart rate, whereas atropine blocks muscarinic receptors on different tissues with varying functional consequences (bradycardia from SA node block versus tachycardia from AV nodal block depending on baseline tone).

• Dose-Response Curves and Pharmacological Principles: The sigmoidal dose-response curve plots drug effect (Y-axis, 0-100%) against log drug concentration (X-axis), revealing two critical parameters: (1) potency, the drug concentration producing 50% of maximum effect (EC50 or ED50), and (2) efficacy (Emax), the maximum achievable response regardless of dose. A drug with lower EC50 is more potent but potency alone does not predict clinical utility—fentanyl is far more potent than morphine (requires smaller doses) but both achieve equal analgesic efficacy when properly dosed. The slope of the dose-response curve (Hill coefficient) determines how dramatically response changes with dose increments: shallow slopes indicate redundant receptor pathways or receptor reserve; steep slopes reflect direct 1:1 receptor-response coupling. Clinical example: anticoagulation with warfarin shows a steep dose-response curve for INR elevation, making small dose adjustments critical to maintain therapeutic range without hemorrhage, whereas antihypertensive beta-blockers display gentler slopes allowing flexibility in dosing.

• Receptor Reserve and Spare Receptors: Tissues often contain more receptors than necessary to produce maximal effect; receptor reserve refers to this surplus. When only 10-30% of available receptors are occupied, full pharmacological response occurs—this reserve provides a "safety margin" preventing profound effects from minor changes in agonist concentration. Importantly, partial agonists (drugs producing <100% maximal response at full receptor occupancy) may achieve clinical equivalence to full agonists in tissues with large receptor reserve. Aripiprazole, a partial dopamine D2 agonist used in schizophrenia, provides antipsychotic effect despite lower intrinsic activity than full D2 agonists, due to dopamine system receptor reserve. Conversely, antagonists (competitive inhibitors with zero intrinsic activity) simply reduce the maximum response achievable by agonists without changing the EC50 in the absence of reversible binding.

• Competitive versus Non-Competitive Inhibition: Competitive antagonism occurs when a drug reversibly binds the same active site as the agonist, increasing the apparent EC50 without reducing Emax—higher agonist concentrations overcome inhibition (rightward shift of the dose-response curve). Clinically, naloxone competitively reverses opioid overdose by occupying mu-opioid receptors and preventing morphine binding; sufficient morphine doses will overcome naloxone's effect. Non-competitive antagonism involves irreversible binding or allosteric interaction, reducing both Emax and shifting the EC50 right; agonist concentration cannot overcome this inhibition. Phenoxybenzamine, an alpha-adrenergic antagonist, covalently binds alpha-1 receptors, necessitating new receptor protein synthesis for reversal—this explains why its effects persist 24+ hours despite short plasma half-life. Understanding this distinction guides drug interactions: competitive antagonists are outcompeted by high agonist concentrations (clinically relevant with potent agonist doses), whereas non-competitive effects prove insurmountable.

• Dose-Limiting Toxicity and Therapeutic Index: As drug doses increase beyond the therapeutic range, side effects emerge through either (1) on-target toxicity (excessive desired effect at high doses) or (2) off-target effects (binding to unintended receptors). Theophylline, a nonselective phosphodiesterase inhibitor, provides therapeutic bronchodilation through airway smooth muscle relaxation but causes seizures and arrhythmias through CNS and cardiac toxicity at high levels, with narrow therapeutic window (10-20 mcg/mL) necessitating level monitoring. The therapeutic index (TI) = TD50/ED50 (ratio of dose producing toxicity in 50% of population to dose producing effect in 50%) or the therapeutic window = (maximum effective concentration/minimum toxic concentration) quantifies safety margin. Drugs with low therapeutic indices (digoxin, lithium, warfarin) require careful dosing and monitoring; those with high indices permit more forgiving dosing (penicillins, statins). This explains why loop diuretics are preferred to thiazides in heart failure despite similar potency—thiazides cause metabolic derangements (hypokalemia, hyperglycemia) at their therapeutic doses due to off-target effects on glucose/electrolyte metabolism, whereas loop diuretics achieve diuresis with fewer metabolic complications.

• Genetic Polymorphisms in Receptor Structure or Function: Genetic variations alter receptor density, affinity, or downstream signaling capacity, explaining variable drug responses among patients receiving identical doses. CYP450 polymorphisms (while primarily affecting pharmacokinetics) indirectly impact pharmacodynamics by altering steady-state drug concentrations; poor metabolizers of warfarin (CYP2C9 variants) achieve higher anticoagulation at standard doses, increasing bleeding risk. Beta-1 adrenergic receptor polymorphisms (Arg389Gly, Gly16Arg) influence beta-blocker efficacy—patients homozygous for Arg389 achieve greater heart rate reduction from metoprolol than those with Gly389. TPMT polymorphisms affect 6-mercaptopurine metabolism but also modulate thiopurine sensitivity through altered metabolite accumulation; heterozygous carriers require dose reduction to avoid toxicity. Pharmacogenomic testing increasingly guides dosing for warfarin, clopidogrel, and thiopurines to optimize pharmacodynamic response.

• Receptor Upregulation and Downregulation (Chronic Drug Exposure): Sustained receptor activation triggers desensitization through multiple mechanisms: phosphorylation of intracellular receptor domains by G protein receptor kinases (GRKs), beta-arrestin binding preventing G protein coupling, and receptor internalization via endocytosis. Clinically, continuous opioid therapy produces tolerance—escalating doses are required to maintain analgesia as mu-opioid receptors desensitize through phosphorylation and internalization. Conversely, upregulation occurs with receptor antagonism or decreased agonist availability: beta-blocker discontinuation causes rebound tachycardia and hypertension due to upregulated beta-adrenergic receptors sensitizing to endogenous catecholamines. Chronic benzodiazepine use desensitizes GABA-A receptors through reduced channel opening probability and receptor downregulation, explaining benzodiazepine dependence and withdrawal seizures upon abrupt cessation.

• Age-Related Changes in Receptor Sensitivity: Elderly patients exhibit altered pharmacodynamic responses independent of age-related changes in drug metabolism or clearance. Reduced beta-adrenergic receptor responsiveness in aging hearts explains why older patients require higher doses of catecholamines to achieve equivalent contractility increases; conversely, heightened CNS sensitivity to benzodiazepines and anticholinergics produces delirium at doses well-tolerated in younger adults. Baroreceptor reflex blunting with age reduces compensatory tachycardia in response to hypotension from vasodilators, increasing syncope risk. Estrogen influences receptor expression and G protein coupling—postmenopausal women show reduced cardioprotective responses to certain medications and altered sympathomimetic sensitivity compared with premenopausal women.

• Pathological States Affecting Receptor Function: Disease states modify receptor expression and pharmacodynamic responses. Congestive heart failure upregulates cardiac sympathetic nervous system; beta-blockers initially worsen cardiac output through loss of compensatory beta-adrenergic support but ultimately improve outcomes through reduced adverse remodeling and neurohormonal deactivation (paradoxical long-term beneficial effect despite initial negative inotropic effect). Septic shock causes tachyphylaxis to catecholamines through multiple mechanisms: receptor desensitization, impaired G protein coupling from nitrosylation, altered second-messenger signaling from sepsis-induced inflammation. Chronic kidney disease alters erythropoietin receptor sensitivity on bone marrow erythroid progenitors, necessitating higher erythropoietin-stimulating agent doses; inflammatory cytokines impair receptor signaling independent of drug concentration.

• Drug-Drug Interactions at the Receptor Level: Two drugs targeting the same receptor pathway produce additive, synergistic, or antagonistic effects depending on mechanism. ACE inhibitors and beta-blockers show additive cardiac effects reducing heart rate and contractility; co-administration achieves lower blood pressure than either alone at equivalent doses. Naloxone and morphine show pure antagonism—naloxone simply blocks morphine's effect without independent activity. NSAIDs and corticosteroids show synergistic gastropathy risk through complementary mechanisms (NSAID-induced prostaglandin inhibition impairing gastric mucus protection + corticosteroid direct mucosal injury), making concurrent use contraindicated despite no direct receptor interaction.

• Dose-Dependent Therapeutic Response: Progressive improvement in target symptom occurs as drug concentration increases from sub-therapeutic to therapeutic range, reflecting increased receptor occupancy. A patient with newly initiated lisinopril for hypertension shows gradual blood pressure reduction over 2-4 weeks as ACE inhibitor effect accumulates; further dose increases produce additional but diminishing blood pressure reductions until maximal effect achieved. Some patients achieve target blood pressure at 10 mg daily (below recommended maximum 40 mg), while others require maximum dosing—this variance reflects inter-individual differences in ACE expression and cardiovascular reactivity rather than drug potency variation.

• Dose-Dependent Adverse Effects: Side effects emerge and intensify as drug concentration exceeds thresholds for off-target receptor binding or excessive on-target effect. Anticholinergic toxicity from high-dose antipsychotics manifests progressively—mild dry mouth and urinary hesitancy at therapeutic doses escalate to urinary retention, constipation, and altered mental status at supratherapeutic levels. Digitalis toxicity demonstrates both on-target toxicity (excessive Na-K-ATPase inhibition producing cardiac arrhythmias) and off-target effects (GI upset, visual disturbances from central effects); narrow therapeutic window means modest dose excess produces severe toxicity. Aspirin overdose shows biphasic dose-response: therapeutic antiplatelet effect at low doses, followed by uncoupling of oxidative phosphorylation causing hyperthermia at high doses.

• Tolerance and Tachyphylaxis: Reduced responsiveness to repeated drug doses appears over hours to days despite maintained drug concentration. Continuous nitrate exposure for angina produces tolerance within 24-48 hours; the patient experiences symptom relief initially then recurrent angina at the same dose as endothelial nitric oxide synthase becomes uncoupled. Nitrate-free intervals (12-14 hours daily) restore responsiveness. Decongestant nasal sprays (phenylephrine, oxymetazoline) produce tolerance within 3-5 days of continuous use as alpha-1 adrenergic receptors desensitize; patients unconsciously escalate use (rebound congestion when stopped), creating physical dependence. Levodopa responsiveness in Parkinson's disease gradually diminishes over years as dopamine neuron loss progresses, requiring dose escalation to maintain motor control.

• Receptor Supersensitivity and Rebound Effects: Abrupt discontinuation after chronic drug use reveals upregulated receptor density through paradoxical worsening of the original condition. Beta-blocker withdrawal produces rebound hypertension and tachycardia within 24-72 hours; upregulated beta-adrenergic receptors now hypersensitive to endogenous catecholamines. Myocardial infarction risk increases 3-fold during this period. Benzodiazepine discontinuation provokes anxiety, insomnia, and potentially seizures as GABA-A receptors remain desensitized during the initial withdrawal period despite absent drug. Gradual tapering allows receptor re-sensitization to occur in parallel with declining drug concentrations, preventing rebound phenomena.

• Partial Agonist Effects: Partial agonists produce seemingly paradoxical clinical responses—they may improve symptoms while possessing lower intrinsic activity than endogenous agonists, and they may paradoxically worsen symptoms in high-agonist-tone states. Aripiprazole in schizophrenia reduces dopamine hyperactivity in mesolimbic pathways (antipsychotic effect) while providing D2 agonism in hypofunctional mesocortical dopamine circuits (cognitive improvement and mood stabilization). Pindolol, a beta-blocker with partial agonist activity, maintains resting heart rate better than pure beta-blockers in bradycardic patients; this same property provided cardiovascular stability in acute MI survivors who might decompensate from pure beta-blockade.

• Hyperresponsiveness in Specific Populations: Certain groups manifest exaggerated pharmacodynamic responses to standard doses. Elderly patients show profound CNS depression from benzodiazepines through increased blood-brain barrier permeability and altered GABA-A receptor sensitivity; a 2 mg lorazepam dose producing mild sedation in a 40-year-old may cause delirium in an 80-year-old. Pediatric patients exhibit paradoxical responses to some drugs—stimulants improve focus in ADHD but cause hyperactivity in young children due to developmental differences in prefrontal cortex dopamine sensitivity. Renally impaired patients accumulate active drug metabolites; morphine produces toxicity in renal failure partially from pharmacokinetic factors (reduced clearance) but also from pharmacodynamic factors (altered blood-brain barrier permeability and central opioid receptor sensitivity).

• Dose-Response Curve Construction and Interpretation: Measuring serial drug effects across dose range reveals individual EC50 and Emax values, critical for personalized dosing. Warfarin dosing requires measuring INR response across dose

Curve-shift questions (the single most tested item)

• Competitive antagonist: parallel rightward shift of the agonist curve, EC50 increases, Emax unchanged — the block is surmountable by more agonist. Naloxone versus morphine is the stem's favorite example.
• Noncompetitive/irreversible antagonist: Emax falls, block is insurmountable (phenoxybenzamine's covalent alpha-blockade — effect outlasts plasma half-life because new receptor synthesis is required).
• Partial agonist alone looks like a lower-Emax curve; added to a full agonist it behaves as a functional antagonist, pulling the response down toward its own ceiling. Buprenorphine precipitating withdrawal in an opioid-dependent patient is the classic vignette.

Definitions examiners try to swap

• Potency (EC50/ED50) ≠ efficacy (Emax): potency is a position on the x-axis, efficacy is the height of the plateau. The common distractor is calling the more potent drug "better" — fentanyl is more potent than morphine, not more efficacious.
• Graded curves yield EC50; quantal (population) curves yield ED50, TD50, LD50. Therapeutic index = TD50/ED50; a narrow index (digoxin, lithium, warfarin, theophylline) is what triggers level monitoring, not low potency.
• Spare receptors make EC50 < Kd — maximal response occurs at submaximal occupancy. This is why partial agonists can be clinically fully effective in reserve-rich tissues.

Associations worth memorizing

• GABA-A modulation: benzodiazepines increase channel-opening frequency and require GABA to be present, giving a ceiling effect; barbiturates increase opening duration and at high doses directly gate the channel without GABA. That GABA-mimetic property is why barbiturate overdose causes fatal respiratory depression while isolated benzodiazepine overdose is usually survivable.
• Flumazenil competitively reverses benzodiazepines at GABA-A but is largely avoided clinically — it precipitates seizures in chronic benzodiazepine users and in co-ingestions (TCAs); supportive care and airway management are the mainstay.
• Inverse agonist reduces constitutive activity below baseline; an antagonist has zero intrinsic activity — do not equate them.
• Beta-blocker overdose with hypotension unresponsive to fluids and catecholamines: glucagon, which activates its own Gs-coupled cardiac receptor and raises cAMP through a pathway parallel to (and therefore bypassing) the blocked beta receptor. High-dose insulin with euglycemia and IV calcium are adjuncts in refractory cases; poison center/toxicology consultation (AAPCC/ACMT) is the parallel best next step.